ArticleCureus2025
Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis cross-sectional questionnaire-based survey assessed the use of Bruton's tyrosine kinase inhibitors (BTKis), clinical decision-making, and barriers to implementation among Indian hematologists managing B-cell lymphomas, identifying practice gaps that require policy interventions. MATERIALS AND
methodsA 28-item structured questionnaire was administered to hematologist-oncologists across India from 1 February 2025 to 31 May 2025. Of 50 invited clinicians, 38 responded (76% response rate). The survey assessed BTKi usage by disease and therapy line, molecular testing patterns, drug selection strategies, adverse event management, discontinuation reasons, and prescribing barriers. Data were analyzed using descriptive statistics with Microsoft Excel (Microsoft Corp., Redmond, WA, USA).
resultsDiffuse large B-cell lymphoma (40%) and chronic lymphocytic leukemia (CLL, 22%) were the most common. BTKis were used as first-line therapy in 92.1% of CLL cases. Generic acalabrutinib showed higher adoption (42.1%) than ibrutinib, mainly due to better safety and cost advantages. Cytogenetic markers were the most influential factor in initiating BTKi (52.63%). Molecular testing adoption exceeded 63%, with TP53, del(17p), and IgHV routinely ordered. For elderly or frail patients, 86.8% preferred BTKis over chemotherapy. Intolerance and financial constraints were the leading causes of discontinuation (36.8% and 34.2%). High cost was the significant barrier (89.47%), followed by side-effect management (42.1%) and drug availability (36.84%). Over 86% anticipate increased use of first-line BTKis within five years.
conclusionsThis survey reveals evidence-based treatment selection and appropriate risk stratification in Indian hematology practice. The predominance of generic acalabrutinib reflects superior safety compared to ibrutinib and cost considerations. Financial constraints driving treatment discontinuation underscore an urgent need for healthcare policy interventions to improve drug accessibility and affordability, ensuring equitable access and optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.